ArticleCancers2024

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.

Takuto Nosaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.